Effects of Dietary Cocoa Powder on Inflammation Markers and Catalase Activity in Participants with Type 2 Diabetes Following a Fast Food Style Meal Challenge by Foster, Megan Raeann
 
   THE EFFECTS OF DIETARY COCOA POWDER ON 
INFLAMMATORY MARKERS AND CATALASE 
ACTIVITY IN PARTICIPANTS WITH TYPE-2 
DIABETES FOLLOWING A FAST FOOD STYLE 
MEAL CHALLENGE  
 
   By 
   MEGAN FOSTER 
   Bachelor of Science in Nutrition: Emphasis in Dietetics  
   Oklahoma State University 
   Stillwater, OK 
   2014 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   MASTER OF SCIENCE  
   May, 2016  
ii 
 
   THE EFFECTS OF DIETARY COCOA POWDER ON 
INFLAMMATORY MARKERS AND CATALASE 
ACTIVITY IN PARTICIPANTS WITH TYPE-2 
DIABETES FOLLOWING A FAST FOOD STYLE 
MEAL CHALLENGE  
 
 
   Thesis  Approved: 
 
   Arpita Basu 
 Thesis Adviser 
   Nancy Betts 
 
   Edralin Lucas 
iii 
Acknowledgements reflect the views of the author and are not endorsed by committee 
members or Oklahoma State University. 
ACKNOWLEDGEMENTS  
 
Dr. Arpita Basu 
 
Dr. Nancy Betts 
 





I would like to express my deepest gratitude to each member who has helped me to 
complete my graduate thesis project.  Dr. Basu spent countless hours guiding and helping 
me.  I have truly learned so much because of her.  I would like to thank Dr. Betts for 
performing the statistical analysis for my experiments as well as for being a member of 
my committee.  I would like to thank Dr. Lucas for being a member of my committee and 
for being an inspiring teacher.  I would also like to thank Sandra Peterson for her 
devotion to the nutrition lab and all of her assistance throughout my experiments.  This 
thesis project would not have been possible without each of you.  Thank you so much for 
your patience and support.  
iv 
 
Name: MEGAN FOSTER   
 
Date of Degree: MAY, 2016 
  
Title of Study:  THE EFFECTS OF DIETARY COCOA POWDER ON 
INFLAMMATORY MARKERS AND CATALASE ACTIVITY IN PARTICIPANTS 
WITH TYPE-2 DIABETES FOLLOWING A FAST FOOD STYLE MEAL 
CHALLENGE  
 
Major Field: NUTRITIONAL SCIENCES 
 
 
Dietary polyphenols, such as those in cocoa, have been shown to counteract chronic 
inflammation in animal models as well as in clinical studies. However, limited data exist on the 
role of dietary cocoa on postprandial inflammation and oxidative stress.  Using a randomized 
placebo-controlled crossover trial, we investigated the postprandial effects of a cocoa beverage 
(960 mg total polyphenols) vs. placebo in participants with type 2 diabetes (n=18; age 
(mean±SE): 56±3y; BMI: 35.3±2.0 kg/m2; 14 women; 4 men) following a high-fat meal 
challenge. Blood draws were conducted at fasting, 30 minutes, 1, 2, 4, and 6 hours of the 
postprandial phase. We measured selected markers of inflammation and catalase enzyme activity 
at these time points using the quantitative sandwich enzyme immunoassay technique, as well as 
non-enzymatic colorimetric assays. Interleukin-18 (IL-18) was shown to be significantly lower at 
1, 4, and 6 hours, while C-reactive protein was lower at 6 hours postprandially after cocoa vs. 
placebo supplementation.  Additionally, catalase activity was lower at 1 hour postprandially (all 
p<0.05). No significant effects were noted in interleukin-6 (IL-6), adiponectin, and nitrite 
concentrations between the two treatments. Thus, cocoa polyphenols may exert modest effects in 
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Diabetes is one of the leading causes of morbidity and mortality in the U.S. (National Diabetes 
Surveillance System, 2012).  The prevalence of diabetes is now 9% in the U.S. population, 
approximately double what it was 20 years ago.  Adults and children with diabetes are at an 
increased risk of developing cardiovascular disease (CVD) (American Diabetes Association, 
2014), which further increases the risk of mortality, as CVD is currently the leading cause of 
death in the U.S. (Centers for Disease Control and Prevention, 2013).   
Many risk factors for developing diabetes such as obesity, poor dietary quality, and lack of 
physical activity, are the same as those for developing CVD (American Heart Association, 2013).  
Some of these risk factors can be decreased through healthy diet and exercise.  Consuming foods 
and beverages high in antioxidants has been found to decrease the risk of developing CVD and to 
delay overall mortality (Bazzano et al. 2002).  Polyphenols found in plants, such as apples, 
berries, coffee, onions, and tea possess antioxidant properties and have been associated with 
cardiovascular benefits (Haytowitz et al. 2014, Scalbert & Williamson 2000).  
Dietary cocoa has gained popularity in nutrition research because of its high polyphenol content 
(Lee, K. W. et al. 2003).  Cocoa powder has been shown to decrease oxidation (Wan et al. 2001, 
Mathur et al. 2002) and improve blood pressure (Taubert et al. 2003, Grassi et al 2005) in clinical 
studies of non-diabetic adults.  It has also been shown to improve circulation in clinical studies of 
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non-diabetics adults (Heiss et al 2003, Westphal et al. 2011) as well as diabetic adults (Balzer et 
al 2008).  Antioxidants have been shown to decrease inflammation (Mates et al. 1999, Mangge et 
al. 2014), and a few studies have shown effects of cocoa powder in reducing inflammation 
(Rahman et al. 2006, Parsaeyan et al. 2014).   
Postprandial metabolism refers to the metabolism that occurs after a meal (American Diabetes 
Association, 2001).  People with type 2 diabetes (T2D) typically have high postprandial plasma 
glucose levels (Woerle et al. 2005) along with high postprandial lipid levels (Mero et al. 1998).  
Studies suggest that postprandial lipidemia increases the risk of developing CVD (Hyson et al. 
2003).  Polyphenols have been shown to reduce postprandial hyperglycemia, hyperinsulinemia, 
and hyperlipidemia (Torronen et al. 2010, Hlebowicz et al. 2007, Yi et al. 2013, Murase et al. 
2012).  Since cocoa powder is one of the highest sources of polyphenols (Lee et al., 2003), it may 
be beneficial in reducing postprandial lipidemia and thus in reducing the risk of developing CVD.  
 
Purpose 
The purpose of this study is to examine the effects of dietary cocoa powder on postprandial 
inflammation markers and catalase activity in participants with type 2 diabetes following a high-







1. Consumption of cocoa powder with a high-fat meal will not affect postprandial blood 
levels of C-reactive protein, Interleukin-6, Interleukin-18, adiponectin, and nitrite when 
compared to controls.  
2. Consumption of cocoa powder with a high-fat meal will not affect postprandial blood 






REVIEW OF LITERATURE 
 
A. Diabetes 
The American Diabetes Association defines diabetes as, “a group of metabolic diseases 
characterized by hyperglycemia resulting from a defect in insulin secretion, insulin action, or 
both.” (American Diabetes Association, 2014).  Nearly 29 million people 20 years or older were 
estimated to have diabetes in the United States in 2012 and diabetes was the seventh leading 
cause of death in the United States in 2010.   In 2003-2006 rates of death among adults with 
diabetes was 1.5 times higher than those without diabetes (National Diabetes Statistic Report, 
2014).  Type 2 diabetes (T2D) is the most common form of diabetes.  Most people with T2D are 
either obese or they have increased central body fat.  Obesity has been associated with insulin 
resistance.  People with diabetes have an increased risk of developing atherosclerosis and other 
vascular diseases, as well as hypertension and abnormal lipoprotein metabolism (American 
Diabetes Association, 2014).  
B. Phytochemicals 
Phytochemicals are plant-based compounds with various physiological functions and have been 
shown to reduce risks of chronic diseases (Scalbert et al. 2000).  Polyphenols are the largest 
group of phytochemicals in the human diet (King & Young 1999), with an average intake of 
about one gram per day in the U.S. (Scalbert et al. 2000).  Flavonoids are a sub-type of 
polyphenols, which have antioxidant properties and subsequent decreases in oxidative stress.  
Subclasses of flavonoids include the following: flavanols, flavonals, flavanones, flavones, 
isoflavones, & anthocyanidins.  Total flavonoid intake is about 132 mg per day in the U.S., with 
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black tea, onions, parsley, and blueberries being some of the main sources (Haytowitz et al. 
2014).  
Most plant foods contain a variety of phytochemicals.  The phytochemical composition can vary 
based on where the plant was grown, its ripeness, storage, and processing.  For example, roasting 
cocoa beans causes a 10-30% reduction in polyphenol content due to exposure to high 
temperatures and oxygen, which accelerates oxidation (Bordiga et al. 2015).  Many foods are not 
eaten whole, but rather included as a part in another food or dish.  The effects of food components 
on the bioavailability of polyphenols are controversial.  It has been suggested that lipid and 
carbohydrates may increase absorption, while fiber may decrease absorption.  The effects of 
protein on polyphenol bioavailability have shown conflicting results depending on the protein and 
polyphenols involved (Bohn, 2014).   For example, in the case of chocolate, dark chocolate 
typically has about two-thirds the polyphenol content of pure cocoa powder, while milk chocolate 
has only about one-third the polyphenols of pure cocoa powder.  The polyphenol content of 
chocolate and cocoa powder vary widely depending on the brand, processing methods that were 
used, and where the cocoa beans originated (Brcanovic et al. 2013).   
Several observational studies reveal significant associations of various types of phytochemical 
intake, such as flavonoids with the risk reduction of chronic diseases.  A prospective study of 
postmenopausal women found that dietary intake of foods high in flavonoids was associated with 
a reduced risk of coronary heart disease (CHD), cardiovascular disease (CVD), and death from all 
causes (Mink et al. 2007).  A study of elderly men found that tea consumption high in flavonoids 
decreased the risk of ischemic heart disease (Arts et al. 2001).   An inverse relationship has been 
found between flavonoid intake and risk of developing lung cancer (Marchand et al. 2000), colon 
cancer (Kyle et al. 2010), and T2D (Liu et al. 2014).  Thus, polyphenols may be suggested to 




C. Antioxidants  
Antioxidants can be defined as “any substance that delays, prevents or removes oxidative damage 
to a target molecule” (Halliwell, 2007).  Antioxidants moderate levels of reactive oxygen species 
(ROS) and are usually reducing agents.  Antioxidants can be either exogenous or endogenous 
(Bouayed et al. 2010).  Exogenous antioxidants include compounds such as vitamin E, vitamin C, 
carotenoids, and polyphenols.  Endogenous antioxidant systems include enzymes, such as 
superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) (Bouayed et al. 
2010).  Several enzymes in the vasculature including NADPH oxidase, uncoupled endothelial 
nitric oxide synthase (eNOS), xanthine oxidase, and the mitochondrial electron chain, produce 
reactive oxygen species (ROS).  Increased ROS have been found in CVD and diabetes (Li et al. 
2014).  Oxidative stress occurs when there are more ROS than antioxidants; and oxidative 
damage occurs when there is damage caused due to oxidative stress (Halliwell, 2007).  Oxidative 
damage contributes to the progression of chronic diseases including atherosclerosis (Li et al. 
2014).   
Catalase (CAT) is an endogenous antioxidant enzyme (Bouayed et al. 2010) that belongs to the 
group of monofunctional heme-containing catalases (Kodydkova et al. 2014).  The primary 
function of CAT is to breakdown hydrogen peroxide into water and oxygen.  CAT is found in all 
aerobic organisms mainly in peroxisomes (Kodydkova et al. 2014).  CAT activity is most 
prominent when hydrogen peroxide levels are high while GPx has been found to be the main 
reducing enzyme for hydrogen peroxide at normal levels (Cohen et al. 1963).  
D. Post-Prandial Metabolism  
Postprandial metabolism signifies the metabolism that occurs after consumption of a meal 
(American Diabetes Association, 2001).  People with T2D typically have high postprandial 
plasma glucose levels (Woerle et al. 2005).   Postprandial glucose concentrations are associated 
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with mortality even more so than fasting glucose concentration (Borch-Johnson et al. 1999).  
Postprandial hyperglycemia is also associated with postprandial lipemia (Mero et al. 1998).  
Studies have shown the associations between impaired postprandial metabolism and coronary 
artery disease (Karpe, 1999).  Even for people who do not have diabetes, but with CHD, higher 
postprandial hyperglycemia has been correlated with progression of atherosclerosis (Sasso et al. 
2004).  
Insulin resistance in diabetes causes an increase in free fatty acids in circulation.  Insulin 
resistance is associated with a failure to suppress hormone sensitive lipase, thus leading to an 
increase in serum endogenous non-esterified fatty acids (Sanders, 2003); it is also associated with 
an increase in lipoprotein lipase, which hydrolyzes chylomicrons in the postprandial state, also 
leading to increased free fatty acids (Hyson et al 2003).  These taken together lead to an increase 
in serum triglycerides and an increase in VLDL production by the liver.  Insulin is also needed to 
inhibit microsomal triglyceride transfer protein, a protein involved in VLDL synthesis in the 
liver, thus also leading to increased VLDL (Choi et al. 2011).  Due to exchange of lipids with 
HDL, high levels of dietary lipids and VLDL can lead to an decrease in HDL and an increase in 
LDL, which leads to increased cardiovascular risks (Hyson et al. 2003).   
After consuming a high-fat meal, the initial rise in serum triglycerides occurs after 10-30 minutes, 
and the postprandial spike in serum triglycerides occurs 3-4 hours after a meal (Lambert, 2012).  
Many studies suggest that postprandial lipidemia increases the risk of developing atherosclerosis 
and CVD (Hyson et al. 2003).  Polyphenols have been shown to reduce postprandial 
hyperglycemia, hyperinsulinemia, and hyperlipidemia (Torronen et al. 2010, Hlebowicz et al. 
2007, Yi et al. 2014, Murase et al. 2012).  Polyphenols may decrease hyperglycemia and 
hyperlipidemia by interacting with digestive enzymes and membrane receptors, activating insulin 
receptors, stimulating insulin secretion, and decreasing pancreatic lipase activity (Fraga et al. 
2010, Marrelli et al. 2013, Hanhineva et al. 2010).   Many polyphenols have been found to bind to 
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digestive enzymes, modulating their activity as well as bind to and decrease the activity of lipases 
(Bandyopadhyay et al. 2012).  In vitro studies have found flavonoids to decrease α-amylase and 
α-glucoosidase activity, two essential enzymes in carbohydrate digestion.  Other polyphenols 
have been found to decrease SGLT1 and GLUT2 glucose transport and to preserve β-cell 
function.  Collectively these actions reduce blood glucose levels by reducing carbohydrate 
absorption (Hanhineva et al. 2010).  However, few studies have been reported on the role of 
dietary polyphenols in postprandial metabolism in human subjects with diabetes. 
E. Inflammation 
Inflammation is part of a non-specific immune response that occurs with injury.  Under normal 
conditions, inflammation is helpful in wound healing, but chronic inflammation can lead to 
disease (Ferrero-Miliani et al. 2006).  Obesity induces a state of low-grade inflammation.  
Inflammation has also been associated with metabolic syndrome, insulin resistance (Inglesson et 
al. 2008), T2D, and CVD, as well as many other chronic conditions (Rodrigues-Hernandez et al. 
2013).  
Obese individuals have higher levels of inflammatory cytokines than normal weight individuals 
(Rodrigues-Hernandez et al. 2013).  Cytokines include a large group of proteins that may promote 
inflammation, suppress it, or exert a combination of the two processes.  Many cytokines are 
produced in adipose tissue, and thus increased body fat can increase their production (Aldhahi et 
al. 2003).  Interleukin-6 (IL-6) is a cytokine that is often used as a biomarker of inflammation in 
research studies, especially involving diabetes and CVD.  It is secreted linearly with adipose 
tissue, more so in intra-abdominal fat than in subcutaneous fat.  IL-6 interferes with insulin 
signaling by decreasing expression of the IRβ (insulin receptor β) subunit and IRS-1 (insulin 
receptor substrate 1) and the GLUT4 glucose transporter (Lagathu et al. 2003).  IL-6 increases 
lipolysis through activation of extracellular signal-related kinases (Yang et al. 2008), and it has 
been shown to decrease lipoprotein lipase (Greenberg et al. 1992, Aldhahi et al. 2003, Trujillo et 
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al. 2004).  Additionally, IL-6 may increase macrophage uptake of lipids (Yudkin et al. 2000, 
Keidar et al. 2001).  These actions of IL-6 contribute to the development of CVD.  Interleukin-18 
(Il-18) is another cytokine that is secreted in response to inflammation, and it has also been 
shown to be associated with several inflammation-associated disorders including atherosclerosis 
(Alboni et al. 2010).   
C-reactive protein (CRP) is an acute-phase reactant that is regulated by cytokines, including IL-6  
(Rodrigues-Hernandez et al. 2013).  CRP is widely measured in clinics to evaluate inflammation.  
CRP has also been shown to be elevated in people with high levels of HbA1c, as is found in 
diabetes (King et al. 2003, Pradhan et al. 2001).  
Adiponectin is a protein produced in adipose tissue that can be classified as a hormone because of 
its effects on other tissues (Guerre-Millo, 2008).  Studies have shown adiponectin to be low in 
patients with heart disease, diabetes, hypertension, and metabolic syndrome.  Adiponectin has 
also been shown to be inversely associated with BMI, as well as with inflammation markers such 
as TNF-α, IL-6, and CRP.  Roles of adiponectin include stimulating nitric oxide (NO) production, 
suppressing superoxide generation within cells, and decreasing uptake of oxidized LDL, thus 
leading to decreased foam cell formation.  Adiponectin has also been shown to be antithrombotic 
and to increase insulin sensitivity (Nishida et al. 2007).   
Nitric oxide (NO) is a cellular signaling molecule produced in the endothelium of healthy blood 
vessels.  NO is also known as “endothelium-relaxing factor”.  However, there are two main forms 
of nitric oxide synthases: endothelium nitric oxide synthase (eNOS) and inducible nitric oxide 
synthase (iNOS).  NO from eNOS is associated with endothelium dilation and platelet anti-
aggregation, while NO from iNOS is associated with inflammation (Forstermann & Sessa 2011, 
Vallance, 1994).   Endothelium dysfunction and insulin resistance often coexist (Yki-Jarvinen, 
1998).  Hyperglycemia in diabetes has been found to increase reactive oxygen species (ROS) 
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leading to endothelium dysfunction.  Endothelium dysfunction and increased ROS lead to 
reduced NO, which leads to vasoconstriction and increased risk of CVD (Pitocco, 2010).  Also, if 
the pathway of synthesis of NO is disturbed, then NOS may also produce reactive oxygen species 
(ROS).  This is because NOS uses NADPH, and in the presence of oxygen a reactive 
superoxyferrous-peroxy ferric complex is formed.  This NADPH and oxygen complex is referred 
to as NADPH oxidase.  If the NOS cofactor or substrate, tetrahydrobiopterin and L-arginine 
respectively, are missing, then this complex can form superoxide anions or hydrogen peroxide.  
NO may then react with superoxide anions to form peroxynitrite, which is highly toxic.  High 
rates of NOS pathway disturbances are often seen with risk factors for atherosclerosis, such as 
smoking, obesity, hypertension, and hypercholesterolemia (Rassaf et al. 2008, Forstermann & Li 
2011).  Insulin plays a part in activating NOS, while NO signaling enhances insulin sensitivity 
(Levine et al. 2012).  Thus, NO has a significant role in the development and progression of T2D.  
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F. Cocoa 
The cocoa bean is a seed of the Theobroma cocoa tree, largely found in Mesoamerica and South 
America.  Cocoa drink was popular among the Mayan and Aztec populations.  The Mayans 
believed that the gods discovered cocoa.  During the 16th century, cocoa drinks were often used as 
a medicine to treat stomach problems in Mesoamerica.  Over the decades, cocoa has been 
believed to cure multiple ailments including colds, insomnia, obesity, scurvy, and stomach cancer 
(Dillinger et al. 2000). 
The antioxidant capacity of cocoa powder is attributed to its phenolic compounds, especially the 
flavonoids.  The flavonoids in cocoa powder have been identified as catechins, epicatechins, 
dimers, and trimers.  Methylxanthines, including caffeine, theobromine, and theophylline, are 
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also present in cocoa powder but they all either have a low antioxidant capacity or could reduce 
the antioxidant capacity of flavonoids (Maleyki et al. 2010).     
It has been found that cocoa powder has more phenolic phytochemicals and a higher antioxidant 
capacity than tea or red wine (Bhagwat et al. 2013, Lee et al. 2003).  In a study by Lee et al., 
cocoa was reported to contain 611 mg of gallic acid equivalents (GAE) and 564 mg of 
epicatechin equivalents (ECE), which was about twice the flavonoid content and antioxidant 
capacity found in red wine, about three times that of green tea, and about four times that of black 
tea (Lee et al. 2003).  
A study by Schroeter and colleagues showed that (-)-epicatichin is likely the flavanol metabolite 
responsible for the cardiovascular effects seen after cocoa consumption.  Pure (-)-epicatechin 
administered to volunteers mimicked the effects of flavanol-rich cocoa.  Long-term intake of 
high-flavanol diets has been shown to promote nitric oxide synthesis (Schroeter et al. 2005).  This 
may be explained by the role of  (-)-epicatechins in inhibiting NADPH oxidase, which as 
explained previously, is shown to decrease NO (Rassaf et al. 2008).  Specifically, (-)-epicatechin 
has been shown to scavenge the O2 -  formed from NADPH oxidases that binds to NO to form 
peroxynitrite, while O-methyl ethers of (-)-epicatechin inhibit NADPH oxidase activity directly 
(Steffen et al. 2007).   
Flavanol intake correlates with decreased risks of CVD, cancer, and diabetes in observational 
studies (Bazzano et al. 2002, Mink et al. 2007, Buijsse et al. 2006, Djoussé et al. 2011, Larsson et 
al. 2012, Mostofsky et al. 2010).  This has also been supported by the traditional dietary cocoa 
consumption among the Kuna Indians living in the San Blas islands off the coast of Panama.  The 
Kuna who live on the islands are habitual cocoa drinkers, a source of approximately 900 mg 
flavanols a day.  This has been shown to be associated with a significantly lower risk of CVD in 
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this island population, compared to those living on the mainland (Bayard et al. 2007).   Many 
other studies have shown benefits of cocoa as illustrated in Tables 2 and 3 below.  
 
Table 2.  Benefits of cocoa on cardiovascular disease (CVD) risk factors in otherwise 
healthy subjects. 
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Many additional studies examining the effect of cocoa powder or chocolate on health outcomes 
have been done in populations at risk for CVD.  
Table 3.  Benefits of cocoa in subjects with cardiovascular disease (CVD) risk factors  
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People with T2D are at an increased risk of developing CVD (American Diabetes Association, 
2014).  This is in part because obesity and T2D are associated with an increase in inflammation 
(Rodrigues-Hernandez et al. 2013) and oxidation of biomolecules (Li et al., 2014).  
Phytochemicals have been shown to decrease inflammation and oxidative stress (Haytowitz et al., 
2014).  Cocoa powder is a rich source of phytochemicals and many studies have shown its 
beneficial effects in reducing inflammation markers (Parsaeyan et al. 2014), improving FMD 
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(Njike et al. 2011), and decreasing oxidation of biomolecules (Baba et al. 2007).  Very few 
studies have examined the effects of cocoa powder postprandially.  Postprandial hyperglycemia 
and hyperlipidemia are common in people with diabetes (Mero et al. 1998).  Recurring 
postprandial hyperlipidemia increases the risks of CVD (Karpe, 1999).  Polyphenols found in 
plant foods and beverages, such as berries, cinnamon, tea, and coffee, have been found to reduce 
hyperglycemia and hyperlipidemia in human studies, (Torronen et al. 2010, Hlebowicz et al. 
2007, Yi et al. 2013), as well as in animal models  (Benn et al. 2015, Qin et al. 2009, Murase et 
al. 2012, Takahashi et al. 2014). 
Keeping in view the role of cocoa in reducing CVD risks in reported long-term clinical trials, 
there exists a strong rationale to examine its effects on postprandial metabolism, specifically on 











3.1 Participants and study design 
Participants were recruited at the Harold Hamm Diabetes Center at OU Health Sciences Center 
and at the Nutritional Sciences Clinical Assessment Unit at Oklahoma State University through 
campus wide email advertisements and physicians referral at Harold Hamm Oklahoma Diabetes 
Center.  Adult type 2 diabetic patients not on insulin therapy were included in this study.  Patients 
with clinical diagnosis of coronary heart disease (CHD), cancer, or neurodegenerative disorders 
were excluded.  Patients on stable blood pressure medications, enlarged waist circumference 
(men>40 inches, women>35 inches), mild to moderate hyperlipidemia (total cholesterol 
<240mg/dL, triglycerides<200 mg/dL) not on hyperlipidemic agents were included.   
Participants came in three different days for this study.  On the first day (screen) patients were 
screened for abdominal adiposity and type 2 diabetes; they were also screened for safety 
parameters, such as liver and renal functions.  On the second visit (Day 1) the patients were 
randomly assigned to consume either a cocoa beverage or control beverage with a high-fat, low 
polyphenol breakfast that was prepared at the clinic.  Blood draws and vascular measurements 
were taken.  On the next visit (Day 2) the patients were crossed over to the other treatment option, 
either the cocoa beverage or control beverage, consumed with a high-fat, low polyphenol 
breakfast that was provided.  The two intervention visits were separated by a one-week washout 
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phase.  On each day of the two-day postprandial phases, patients arrived at the clinic around 7:30 
AM for a fasting blood draw, after which they consumed the breakfast with or without cocoa 
within 20-25 minutes, followed by postprandial blood draws.  At each visit blood pressure and 
blood draws were taken at fasting, 1, 2, 4, & 6 hours postprandial.  Subjects were monitored 
throughout the 6-hour postprandial phase at the clinic.  Subjects were not allowed to eat or drink 
any other food or beverage, except water that was provided, during that time.  Lunch was 
provided at the end of the six hours.  
 
3.2 Meal and beverage composition 
The breakfast meal consisted of one egg yolk, two slices of white bread with 13 grams of butter, 
one banana, and one pork sausage patty.  The breakfast provided a total of 766 kcals and 50 
grams of fat.  As shown in Table 4, the cocoa and control beverages were similar in calories and 
fat, and while carbohydrates and protein were higher in the cocoa beverage, the ratio of 
carbohydrate to protein was nearly identical between the two beverages.  The cocoa beverage 
contained significantly more polyphenols than the control beverage (960 vs 110 mg).  The cocoa 
beverage contained flavanols, proanthocyanidins, epicatechins, and catechins (480 mg, 201 mg, 
40 mg, and 18 mg respectively), while the control contained none or insignificant amounts of 





3.3 CRP, IL-6, IL-18, adiponectin, nitrite, and catalase 
CRP values were previously measured using freshly drawn blood samples from 
participants in this study at the Oklahoma University Medical Center (OUMC) using 
standard clinical chemistry.   
Using stored samples, IL-6, IL-18, and adiponectin were measured using ELISA kits 
(R&D Systems, Minneapolis, MN) based on the manufacturer’s protocol.  For the ELISA 
assay, 100 µL of Assay Diluent, then 100 µL of sample was added to each well in use.  
The plate was then covered with a sealer and incubated at room temperature for two 
hours.  After incubation the plate was aspirated and washed four times before 200 µL 
Conjugate was added to each well in use.  The plate was then covered with a plate sealer 
and incubated at room temperature for an additional two hours.  After incubation the 
plate was again aspirated and washed four times.  Next, 200 µL Substrate Solution was 
added to each well in use and the plate was incubated at room temperature for 20 
minutes.  Finally, 50 µL of Stop solution was added to each well and absorbance was 
read on a plate reader within 30 minutes at 540 or 570 nm. 
Nitrite was measured using the Griess Reagent System (Promega BioSciences, LLC. San 
Luis Obispo, CA) based on the manufacturer’s protocol.  First, 50 µL of each sample was 
added in duplicate.  Using a multichannel pipettor, 50 µL of Sulfanilamide Solution was 
added to each well in use followed by eight minutes of incubation protected from light.  
Using a multichannel pipettor, 50 µL of N-1-napthylethylenediame dihydrochloride 
(NED) was added to each well in use followed by eight minutes of incubation protected 
from light.  Absorbance was immediately measured on a plate reader at 550 nm. 
21 
 
Catalase enzyme activity was measured using the Cayman Chemical Company Catalase 
Assay Kit (Ann Arbor, Michigan) based on the manufacturer’s protocol.  Each sample 
was diluted in Phosphate Buffer Solution 1:10.  For each sample 100 µL of diluted Assay 
Buffer, 30µL methanol, and 20 µL of sample were pipetted into wells in duplicate.  The 
reaction was started by adding 20 µL diluted hydrogen peroxide to all wells being used 
and then the plate was incubated on a plate shaker for 20 minutes.  Then 30 µL of 
potassium hydroxide, followed by 30 µL of catalase purpald, was added to each well and 
the plate was returned to the plate shaker 10 minutes of incubation.  Following the 
addition of 10 µL of catalase potassium periodate to each well being used, the plate was 
incubated on the plate shaker for an additional five minutes.  Absorbance was 
immediately measured on a plate reader at 540 nm.  
 
Statistical analysis 
Data were analyzed by repeated measures ANOVA using SPSS software with a 
significance level set at p < 0.05.  All data were expressed as means ± standard error.  
The objective was to identify significant differences in the means of inflammation 
markers and catalase at each time point within each group, as well as to identify 










Among the participants screened, 18 met the inclusion and exclusion criteria and were invited to 
participate in the study.  Tables 5a & b show the baseline characteristics of the participants who 
completed the study. All participants had T2D and were not on insulin therapy, but the majority 
(83%) were on oral hypoglycemic agents.  Over half of the participants (56%) were on 
Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers.  Five 
participants were on statins or fibrates.  Additionally, a few participants were on diuretics, 
calcium channel blockers, or regularly took aspirin or multivitamins.  All participants were 
overweight and had enlarged waist circumference.  Overall, the participants consumed a high-fat 
diet (~37% fat).  Fruit and vegetable intakes were low among these participants, averaging 0.6 
and 1.6 cups per day respectively, in comparison to the USDA recommendations for this age 
group (1.5-2 cups per day fruits and 2-2.5 cup per day vegetables) (United States Department of 
Agriculture, 2010).  
Interleukin-18 (IL-18) 
As shown in Figure 1, serum levels of IL-18 were significantly different between cocoa and 
placebo at one, four and six hours postprandial (p<0.05).  At these time points, cocoa intervention 
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resulted in lower levels of IL-18 compared to the placebo treatment.  These results persisted after 
adjusting for BMI and HbA1c as covariates. 
Catalase activity 
As shown in Figure 2, serum catalase activity was significantly different between cocoa and 
placebo at one hour postprandial (p<0.05).  At this time point, cocoa intervention resulted in a 
lower catalase activity compared to the placebo treatment.  These results persisted after adjusting 
for BMI and HbA1c as covariates. 
C-reactive protein (CRP) 
As shown in Figure 3, serum levels of CRP were significantly different between cocoa and 
placebo only at six hours postprandial (p<0.05).  At this time point, cocoa intervention resulted in 
lower levels of CRP compared to the placebo treatment.  These results persisted after adjusting 
for BMI and HbA1c as covariates. 
Adiponectin, Interleukin-6 (IL-6), Nitrite 
As shown in Figures 4, 5, and 6, serum IL-6, adiponectin, and nitrite did not show any significant 







Table 4.  Composition of the cocoa and placebo powder. 
  Cocoa Placebo 
Serving Size, g 20 12 
Calories, kcal 67 66 
Fat, g 4.7 5 
Proein, g 2.7 1.1 
Carbohydrates, g 9.6 4 
Carbohydrates: 
Protein 3.06:01 3.06:01 
Total Polyphenols, mg 960 110 
Total Flavanols, mg 480 <0.1 
Proanthocyanidins 
(PAC) 1-10, mg 201 <0.001 
Epicatichins, mg 40 0 
Catechins, mg 18 0 











Table 5a. Baseline Characteristics: Biochemical Variables and Blood Pressure, Mean +SEM 
Variable Value 
N (Gender, M/F) 18 (4/14) 
Age, y  56+3.2 
Weight, kg 100+12 
BMI, kg/m2 35.3+2.0 
Waist Circumference, inches 45+1.8 
Glucose, mg/dL 136+16 
Insulin, mU/L 14.8+2.6 
Insulin resistance (HOMA-IR) 3.5+0.9 
HbA1c, % 8.2+0.6 
Total Cholesterol, mg/dL 188+11 
LDL-cholesterol, mg/dL 112+11 
HDL-cholesterol, mg/dL 46+2.5 
LDL:HDL 2.54+0.24 
Triglycerides, mg/dL 140+13 
hs CRP, mg/dL 5.3+1.2 
Systolic blood pressure, mm Hg 144+5.5 
Diastolic blood pressure, mm Hg 85+3.0 
Small artery elasticity index, mL/mmHg x 100 5.6+3.6 
Large artery elasticity index, mL/mmHg x 10 17+7.4 
 
Footnote: BMI - body mass index; HOMA-IR – homeostatic model assessment-insulin resistance; 
HbA1c – hemoglobin A1c; LDL – low-density lipoprotein; HDL – high-density lipoprotein; hs 






Table 5b. Baseline Characteristics: Medication/Supplement Use  
Medication/supplement use, n (%) 
Insulin 0 (0) 
Oral hypoglycemic agents 15 (83) 
Statins/fibrates 5 (28) 
Calcium Channel Blockers 3 (17) 
Angiotensin-converting enzyme 
inhibitors or angiotensin II receptor 
blockers 10 (56) 
Diuretics 2 (11) 
Aspirin 6 (33) 
Multivitamin/minerals 6 (33) 
Botanical supplements 2 (11) 
 
Table 5c. Baseline Characteristics: Food Intake 
Macronutrient and food intake, mean + SEM 
Energy, kcal 2216+198 
Carbohydrates, g  263+38 
Total fats, g  92+8 
Protein, g  94+9 
Fiber, g 30+9 
Fruit servings, g/day 144±52 








Figure 1. Postprandial serum concentrations of Interleukin-18 (pg/L) following a high-fat meal 
challenge with or without cocoa beverage.  Data shown as means±SE.  *p<0.05 at one, four, and 
six hours.  
 
 
Figure 2. Postprandial serum catalase activity (nmol/min/ml) following a high-fat meal challenge 


































































Figure 3. Postprandial serum concentrations of C-Reactive Protein (mg/L) following a high-fat 
meal challenge with or without cocoa powder beverage.  Data shown as means±SE.  P<0.05 at 6 
hours. 
 
Figure 4. Postprandial serum concentrations of adiponectin (mg/L) following a high-fat meal 

























































Figure 5. Postprandial serum concentrations of Interleukin-6 (µg/L) following a high-fat meal 
challenge with or without cocoa powder beverage.  Data shown as means±SE. 
 
 
Figure 6.  Postprandial concentrations of nitrite (µM) following a high-fat meal challenge with or 














































Table 6. The effects of cocoa powder vs. placebo on inflammation markers and catalase 
activity in participants with type 2 diabetes following a high fat meal challenge.  Data 
presented as mean + standard error of the mean.  
 PLACEBO 
 
COCOA P value 
C-Reactive Protein (mg/L)    
       Fasting 3.75+0.79 3.25+0.68 0.110 
       1 hr 3.99+0.80 3.27+0.70 0.143 
       2 hr 3.99+0.74 3.35+0.71 0.187 
       4 hr 3.76+0.76 3.33+0.76 0.186 
       6 hr 4.00+0.79 3.11+0.73 0.040 
    
Interleukin-6 (µg/L)    
       Fasting 0.89+0.11 0.77+0.03 0.355 
       1 hr 0.79+0.04 0.72+0.01 0.163 
       2 hr 0.72+0.04 0.77+0.02 0.258 
       4 hr 0.94+0.13 0.80+0.06 0.353 
       6 hr 0.84+0.09 0.76+0.03 0.265 
    
Adiponectin (mg/L)    
       Fasting 2.03+0.31 2.09+0.25 0.729 
       1 hr 1.96+0.27 2.09+0.21 0.459 
       2 hr 2.06+0.24 1.99+0.20 0.721 
       4 hr 1.94+0.20 2.08+0.23 0.518 
       6 hr 2.36+0.21 1.99+22 0.139 
    
Interleukin-18 (pg/L)    
       Fasting 303.06+12.98 300.33+12.29 0.342 
       1 hr 302.44+11.03 278.78+10.96 0.032 
       2 hr 290.28+12.02 286.11+11.76 0.741 
       4 hr 324.72+13.22 267.06+8.48 0.001 
       6 hr 338.61+14.89 250.00+9.16 0.000 
    
Nitrite (µg/L)    
       Fasting 8.35+4.56 6.19+1.48 0.542 
       1 hr 10.58+4.01 11.11+2.68 0.890 
       2 hr 14.20+3.73 13.06+1.71 0.666 
       4 hr 17.71+4.15 13.74+2.30 0.192 
       6 hr 13.83+3.04 12.23+2.32 0.311 
    
Catalase (nmol/min/ml)    
       Fasting 19.58+3.13 29.22+5.23 0.066 
       1 hr 35.14+6.40 15.58+1.90 0.008 
       2 hr 28.24+3.47 25.23+5.04 0.320 
       4 hr 33.92+7.86 22.34+3.80 0.091 







To our knowledge, this is the first randomized placebo-controlled double-blind clinical 
trial to examine the postprandial effects of dietary cocoa powder on inflammation markers and 
catalase activity in participants with T2D following a high-fat meal challenge.  In this study, we 
examined effects of cocoa on inflammatory markers that have been shown to be modulated by 
high-fat meals, mostly in non-diabetic adults in other studies.  Interestingly, our study revealed 
cocoa supplementation following a fast food style high-fat meal challenge to significantly lower 
CRP later in the postprandial phase (only at six hours), while IL-18 levels were lower throughout 
the postprandial phase (one, four and six hours).  No significant effects were found in levels of 
IL-6, adiponectin, and nitrite between the cocoa and placebo groups at any time point.  Finally, as 
a biomarker of antioxidant capacity, catalase activity was lower, though only in the early 
postprandial phase (one hour) following cocoa vs. placebo supplementation. 
Inflammation is part of an immune response that occurs with injury (Ferrero-Miliani et al. 
2006).  Obesity induces a state of chronic low-grade inflammation that can lead to metabolic 
syndrome, insulin resistance, T2D, and CVD, as well as many other chronic conditions (Inglesson 
et al. 2008, Rodrigues-Hernandez et al. 2013).  Obesity and inflammation lead to higher levels of 
inflammatory cytokines (Rodrigues-Hernandez et al. 2013, Amato et al. 2014), including CRP 
(Visser et al. 1999), IL-18 (Alboni et al. 2010), and IL-6 (Aldhahi et al. 2003), and lower levels of 
adiponectin (Nishida et al. 2007).  Phytochemicals, such as those found in cocoa, have been 
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shown to reduce inflammation, and thus may be a useful treatment in prevention and management 
of chronic diseases (Rahman et al. 2006, Wang et al. 2014).  In previously reported studies, 
dietary cocoa powder has been shown to reduce blood pressure (Rostami et al. 2015), total 
cholesterol (Mellor et al. 2010), and inflammation markers (Parsaeyan et al. 2014) in subjects 
with T2D.  Cocoa powder has also been shown to increase HDL cholesterol (Baba et al. 2007) 
and flow-mediated dilation (Grassi et al. 2005) in subjects with CVD risk factors.  Additionally, 
epidemiological studies have found cocoa consumption to be inversely correlated with the 
development of T2D (Zamora-Ros et al. 2013, Matsumoto et al. 2015) and CVD (Buijsse et al. 
2010, Djousse et al. 2011). 
Elevated serum CRP has been correlated with increased risk of developing insulin 
resistance (Ydkin et al. 1999), T2D (Pradham et al. 2001), and CHD (Mendall et al. 1996, 
Kaptoge et al. 2010).  It is a commonly measured biomarker of inflammation in clinical studies 
(Salazar et al. 2014).  Our study found that consuming cocoa beverage with a fast food style high-
fat meal significantly lowered serum CRP, but only at six hours postprandial.  Other studies have 
found interventions with cocoa to decrease CRP in overweight subjects (Stote et al. 2012) or 
those with T2D (Parseayan et al. 2014), while some studies have shown no effects of cocoa 
supplementation on CRP (Mathur et al. 2002, Monagas et al. 2009).  However, none of these 
were postprandial studies, and keeping in view the role of impaired postprandial metabolism and 
inflammation in T2D, our study reveals some protective effects of cocoa, and this needs further 
investigation in larger trials of T2D.   
  Elevated serum IL-18 has also been correlated with obesity and T2D (Herder et al. 2011, 
Amato et al. 2014).  We observed lower levels of IL-18 at one, four, and six hours postprandial in 
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the cocoa group compared to placebo.  In observational studies, high flavonoid intake has been 
correlated with lower levels of IL-18 in the U.S. Women’s Health Study (Landberg et al. 2011).  
Other clinical studies examining effects of diets high in polyphenols, as well as individual 
polyphenol-containing foods and beverages have also shown a decrease in IL-18 in adults with 
CVD risk factors.  The Mediterranean Diet, high in fruits and vegetables, olive oil and other 
sources of polyphenols, has been shown to reduce levels of IL-18 in adults with metabolic 
syndrome (Richard et al. 2013, Espisito et al. 2004).  Similar effects were also noted with red 
wine, bing cherry, or soy consumption (Marfella et a. 2006, Kelley et al. 2012, Azadbakht et al. 
2007).  Furthermore, resveratrol has been shown to decrease IL-18 levels in human aortic smooth 
muscle cells (Venkatessan et al. 2009) and in animal liver cancer cells (Salado et al. 2011).  Thus, 
our study findings are supported by previously reported studies on the effects of polyphenols on 
inflammation, though further studies are needed in diabetes. 
Interleukin-6 (IL-6) has been shown to increase linearly with adiposity (Aldhahi et al. 
2003, Amato et al. 2014) and elevated levels have been correlated with insulin resistance and 
T2D (Yudkin et al. 1999, Duncan et al. 2003, Pradhan et al. 2003).  Our study revealed no 
significant difference in IL-6 between cocoa and placebo treatment at any time point.  However, 
other studies have shown cocoa supplementation to decrease IL-6 levels, such as in obese adults 
and in those with T2D (Stote et al. 2012, Parseayan et al. 2014) at doses equal to or slightly 
higher than our current study.  Cocoa supplementation has also been shown to decrease IL-6 in 
male C57BL/6J mice fed a high-fat diet for ten weeks (Gu et al. 2014), and in healthy female 
Wistar rats after seven weeks (Perez-Berezo et al. 2012).  Thus, our null findings may be 
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explained by the postprandial design, small sample size and the high-fat meal challenge as a 
‘primary’ intervention followed by assessing the ‘secondary’ effects of cocoa supplementation. 
Adiponectin, an anti-inflammatory cytokine, has been shown to be reduced with elevated 
BMI (Amato et al. 2014), and low levels have been correlated with increased risks of CHD, T2D, 
hypertension and metabolic syndrome (Nishida et al. 2007, Herder et al. 2011).  Adiponectin has 
also been found to be inversely correlated with IL-6 and CRP levels in cross- sectional studies 
(Engeli et al. 2003, Krakoff et al. 2003).  Our study revealed no significant difference in 
postprandial levels of adiponectin between cocoa and placebo.  Other trials have revealed no 
effect on adiponectin levels after a higher dose of cocoa powder than in the present study for two 
weeks in hypertensive adults (Muniyappa et al. 2008), or after four weeks of a high dose of 
freeze-dried strawberry powder in women with metabolic syndrome (Basu et al. 2009).  Studies 
have shown polyphenol supplementation to increase adiponectin levels and expression of 
adiponectin gene in male C57BL/6J mice (Gu et al. 2014, Heber et al. 2015), or have no effect in 
obese Sprague Dawley female rats (Shen et al. 2012) and human adipose tissue cells (Derdemezis 
et al. 2011).  Thus, effects of polyphenols on adiponectin are conflicting and need further 
investigation. 
Nitric oxide (NO) is a cellular signaling molecule important in endothelium dilation 
(Vallance, 1994).  There are two main forms of nitric oxide synthases; these are endothelium 
nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS).  NO from eNOS is 
associated with endothelium dilation, while NO from iNOS is associated with inflammation 
(Forstermann & Sessa 2011).  Excess NO synthesis, such as under conditions of elevated lipids, 
hypertension, hyperglycemia and other CVD risk factors, has been associated with the formation 
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of the peroxynitrite radical which is an oxidizing agent, and also been shown to upregulate 
inflammation and decrease endothelial function (Valco, et al. 2007). 
NO has a short half-life of only a few seconds, therefore typically measured as nitrite, 
one of two more stable breakdown components of NO (Liu et al. 1998, Shiva 2013, Lundberg et 
al. 2008).  Our study revealed no significant difference between cocoa and placebo groups for 
levels of nitrite.  However, diets high in polyphenols have been correlated with increased 
circulating NO in a Spanish cohort study (Medina-Ramon et al. 2015).  In addition, clinical trials 
have shown cocoa supplementation to increase circulating NO levels after two hours (Heiss et al. 
2003), and to increase flow-mediated dilation after six weeks at a similar dose to the present 
study (Njike et al. 2011) and after 15 days at a lower dose (Grassi et al. 2005).  None of these 
were postprandial studies involving a high-fat meal.  Again, our null findings may have been due 
to our small sample size or due to the co-administration of a high-fat meal along with cocoa 
intervention.  
Catalase is an endogenous antioxidant enzyme important in preventing oxidative stress 
(Valko et al. 2007).  Its main function is to reduce hydrogen peroxide into water and oxygen 
(Kodydkova et al. 2014).  We observed lower levels of catalase activity at one hour postprandial 
in the cocoa group compared to the placebo.  Reduced catalase activity may be due to a ‘sparing 
effect’ of cocoa polyphenols on antioxidant enzymes.  Cocoa supplementation in patients with 
T2D resulted in reduced glutathione and catalase levels after three months of treatment (Ramirez-
Sanchez et al. 2013).  On the other hand, cocoa supplementation has shown to increase catalase 
levels in arthritic female Wister rats (Ramos-Romero et al 2012), or have no effect in male 
diabetic Zucker rats (Cordero-Herrera et al. 2015).  Keeping in view the known synergistic effects 
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of polyphenols with antioxidant factors in vivo (Scalbert et al. 2005, Kang et al. 2013), future 
studies must examine these associations in diabetes. 
Our study has some limitations, which must be considered when interpreting our results.  
One limitation is the small sample size of only eighteen participants.  Having a larger sample size 
would have increased our power and generalizability.  We only had 85 out of 180 samples for IL-
6 analysis.  Having a complete set of data for this biomarker would have increased our power for 
detecting differences.  Another limitation of our study is that we did not compare the findings in 
our diabetic subjects with non-diabetic controls.  We only used one dose of cocoa powder, and 
thus a dose-response effect would be of great interest in future studies.  We also measured 
selected biomarkers of inflammation, and did not examine changes in other markers, such as 
interleukin-1β, interleukin-8, interleuking-10, TNF-α, or E-selectin, and this remains to be 
explored in larger trials in diabetes   
Overall, we reject the null hypothesis that cocoa powder would have no affect on 
inflammation markers, as we have demonstrated that cocoa powder supplementation with a high-
fat meal lowers selected biomarkers of inflammation when compared to the placebo treatment.  
We also reject the null hypothesis that cocoa powder would have no effect on catalase activity, as 
we saw a decrease in catalase activity with cocoa supplementation in the presence of a high-fat 
meal vs. placebo.  
 
Applications and Conclusions 
Overall, our study findings show modest anti-inflammatory effects of cocoa in lowering 
serum CRP and IL-18 at one or more time points during the six-hour postprandial phase in adults 
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with type 2 diabetes.  We also observed selected modulation of catalase activity in early 
postprandial phase following cocoa supplementation vs. placebo.  Thus, based on our findings 
cocoa supplementation in the presence of a high-fat meal challenge may offer some protective 
effects against postprandial inflammation.  Further research is needed to confirm these findings in 
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